


Modified Delphi Panel Consensus Guidance and Essential Strategies on the Prevention and Management of Nausea and Vomiting in Patients Treated With Zolbetuximab + Chemotherapy⁵




- An international RAND/UCLA modified Delphi panel included 15 clinicians
 - Panelists^a were selected based on their experience in the zolbetuximab clinical trials

Prior to and During First Infusion



Second and Subsequent Infusions



^aExperts from the US, Europe, Japan, and South Korea reviewed 382 scenarios, reaching an agreement in 85% (n=324). ^bLorazepam, olanzapine, or metoclopramide.

5-HT₃ RA, 5-hydroxytryptamine (serotonin) receptor subtype 3 antagonist; AE, adverse event; C, cycle; D, day; Hrs, hours; H₂, histamine subtype H₂ receptor; HCP, healthcare provider; IRR, infusion-related reaction; IV, intravenous; mFOLFOX6, modified folinic acid, fluorouracil, and oxaliplatin regimen; NCI-CTCAE v5.0, National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0; NK-1 RA, neurokinin subtype 1 receptor antagonist; OS, overall survival; PFS, progression-free survival; PI, prescribing information; PPI, proton pump inhibitor; RAND/UCLA, RAND Corporation/University of California, Los Angeles; TEAE, treatment-emergent adverse event; US, United States.

1. Zolbetuximab placeholder reference for SmPC. 2. Shitara K, et al. ASCO GI 2024. Abstract #372. 3. Shitara K, et al. Lancet. 2023;401(10389):1655-1668. 4. Shah MA, et al. Nat Med. 2023;29(8):2133-2141. 5. Klemperer SJ, et al. ESMO Gastrointest Oncol 2025; 7: 100131. 6. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Accessed January 20, 2025. 7. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 20, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.